Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Up 285.7% in December

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 121,100 shares, an increase of 285.7% from the November 30th total of 31,400 shares. Based on an average daily volume of 61,300 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC grew its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Trading Up 25.3 %

Shares of EVAX stock traded up $0.21 on Friday, hitting $1.06. 8,476,896 shares of the stock traded hands, compared to its average volume of 267,984. The firm’s 50-day moving average price is $1.76 and its two-hundred day moving average price is $2.55. Evaxion Biotech A/S has a twelve month low of $0.84 and a twelve month high of $13.61. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The stock has a market capitalization of $6.22 million, a PE ratio of -3.66 and a beta of -0.39.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.08. The company had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. As a group, analysts anticipate that Evaxion Biotech A/S will post -0.15 EPS for the current year.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.